Introduction: Small molecule protein kinase inhibitors (KIs) are a class of drugs with complex
and unconventional physiochemical and pharmacokinetic characteristics. Cytochrome P450 …

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable
and clear relationships exist between exposure and treatment outcomes, fixed dosing is still …

(1) Introduction: Pharmacokinetic boosting of kinase inhibitors can be a strategy to enhance
drug exposure and to reduce dose and associated treatment costs. Most kinase inhibitors …

Introduction: Orally administered small molecule kinase inhibitors (KI) are a key class of
targeted anti-cancer medicines that have contributed substantially to improved survival …

Protein kinase inhibitors share pharmacokinetic (PK) pathways among themselves. They are
all metabolized by several cytochromes P450 (CYP). For most of them, CYP3A4 is the …

Protein kinase inhibitors (PKI) are a growing class of anticancer agents. They are prescribed
with flat doses, and their oral administration is associated with interindividual variability in …

The evaluation of a compound's pharmacokinetics (PK) and toxicokinetics (TK) is one critical
component in understanding how a drug works in vivo. In the 1990s, one of the primary …

Small molecule kinase inhibitors are one of the fastest growing classes of drugs, which are
approved by the US Food and Drug Administration (FDA) for cancer and noncancer …

Small molecule kinase inhibitors (KIs) are a rapidly expanding class of narrow therapeutic
index antineoplastic drugs that exhibit substantial inter-individual variability in exposure …

The treatment of many malignancies has been improved in recent years by the introduction
of molecular targeted therapies. These drugs interact preferentially with specific targets that …